What is Duchenne Muscular Dystrophy?

Duchenne Muscular Dystrophy (DMD) is a genetic disorder that affects thousands of families worldwide. It primarily impacts boys, causing muscle degeneration and weakness over...

About our Mission

Many people in the world do not know what Duchenne muscular dystrophy is. Because only one in every 5,000 boys gets this disease. However, families and their surroundings whose children struggle with this disease have to live with the stress of this disease every day. We call them DMD Warriors.

DMDWarrior.com was established to raise awareness of this disease worldwide, facilitate access to treatments, and ensure that treatment costs are affordable.

dmd warrior dmdwarrior

What is our purpose?

One in every 5,000 children in the world is born with DMD, and many families only realize their child has the disease when they are 3-4 years old. FDA-approved treatments for DMD are too expensive for families to afford. Our goal is to reduce treatment costs and have the costs covered by the government.

Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

Home

Raising Awareness on Social Media

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

News & Articles

The Challenge of Getting DMD Gene Therapy: Is Geography Destiny?

Why are DMD gene therapies so expensive? Over the last decade, significant advancements have been made in the development of gene therapies for DMD,...

Satellos Announces Completed Enrollment of Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

Satellos Bioscience, a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it...

Sarcomatrix to Present its Latest Advancements in the Development of its Lead Drug Candidate, S-969

Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO & Investor...

Upcoming Exon 44 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy

Exon 44 skipping therapies represent a promising area in the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness...

Percheron Therapeutics Announces Terminated of ATL1102 Study for DMD

“One way or other, we don’t think ATL-1102 can remain the centerpiece of the story put forward to investors,” Garner told investors in a...